

PTO/SB/21 (08-00)

Please type a plus sign (+) in this box → ☐

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM***(to be used for all correspondence after initial filing)*

Total Number Of Pages In This Submission

14

Application Number

09/665,510

Filing Date

September 19, 2000

First Named Inventor

Ralph T. KUBO

Group Art Unit

To Be Assigned

Examiner Name

To Be Assigned

Attorney Docket No.

399632000325

ENCLOSURES (check all that apply)☐ Fee Transmittal Form☐ Assignment Papers
(for an Application)☐ After Allowance Communication to
Group☐ Fee Attached☐ Drawing(s)☐ Appeal Communication to Board of
Appeals and Interferences☐ Amendment / Reply☐ Licensing-related Papers☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)☐ After Final☐ Petition☐ Proprietary Information☐ Affidavits/declarations☐ Petition to Convert to a
Provisional Application☐ Status Letter☐ Extension of Time Request☐ Power of Attorney, Revocation
Change of Correspondence Address☒ Other Enclosure(s) (please identify
below): Return postcard☐ Express Abandonment Request☐ Terminal Disclaimer☐ Request for Refund☒ Information Disclosure Statement;
PTO form 1449; copy of European
Search Report; and 60 references☐ CD, Number of CD(s) _____☐ Certified Copy of Priority Document(s)

Remarks

☐ Response to Missing Parts/
Incomplete Application☐ Response to Missing Parts
under 37 CFR 1.52 or 1.53**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**Firm
or
Individual NameBruce D. Grant
Registration No. 47,608

Signature

Date

November 15, 2001

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on November 15, 2001.

Garee A. Haney

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT #6
Docket No. 399632000325

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on November 15, 2001.

Garee A. Haney
Garee A. Haney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ralph T. KUBO et al.

Serial No.: 09/665,510

Filing Date: September 19, 2000

For: HLA BINDING PEPTIDES AND THEIR
USES

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith, except documents Nos. 2, 9, 28 and 42, which will follow. The Examiner is requested to make these documents of record.

The documents Nos. 15, 23 and 64, listed on the attached Form PTO-1449 were cited in a Search Report (copy attached) directed to a counterpart international or foreign application.

This Information Disclosure Statement is submitted:

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 399632000325. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Dated: November 15, 2001

Respectfully submitted,

By: 

Bruce D. Grant
Registration No. 47,608

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7962
Facsimile: (858) 720-5125



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 399632000325	Application Number 09/665,510
	Applicant Ralph T. KUBO et al.	
	Filing Date September 19, 2000	Group Art Unit To Be Assigned
	Mailing Date: November __, 2001	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	04/1998	5,736,142	Sette et al.	424	185.1	
	2.	03/2000	6,037,135	Kubo et al.	435	7.27	
	3.	06/2000	6,075,122	Cheever et al.	530	352	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	4.	Alexander et al., J. Immunol. (1997) 159:4753-4761
	5.	Altfeld et al., J. Virol. (2001) 75:1301-1311
	6.	Benjamin et al., Nature (1991) 351:74-77
	7.	Bergmann et al., J. Virol. (1994) 68:5306-5310
	8.	Bertoni et al., J. Clin. Invest. (1997) 100:503-513
	9.	Boel et al., Immunity (1995) 2:167
	10.	Boon et al., Int. J. Cancer (1993) 54:177-180
	11.	Castellanos et al., Gynecologic Oncology (2001) 82:77-83
	12.	Castellanos et al., Oncology/Hematology (2001) 39:133-138
	13.	Chang et al., J. Immunol. (1999) 162:1156-1164
	14.	Chen and Parham, Nature (1989) 337:743-745
	15.	Culmann et al., J. Immunol. (1991) 146(5):1560-1565
	16.	Del Val et al., Cell (1991) 66:1145-1153
	17.	Diepolder et al., J. Virol. (1997) 71(8):6011-6019

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632000325

Application Number 09/665,510

Applicant

Ralph T. KUBO et al.

Filing Date September 19, 2000

Group Art Unit To Be Assigned

Mailing Date: November __, 2001

- | | |
|-----|---|
| 18. | Ding et al., Immunity (1998) 8:403-411 |
| 19. | Doolan et al., Immunity (1997) 7:97-112 |
| 20. | Doolan et al., J. Immunol. (2000) 165:1123-1137 |
| 21. | Eisenlohr et al., J. Exp. Med. (1992) 175:481-487 |
| 22. | Gambacorti-Passerini et al., Clin. Cancer Res. (1997) 3:675-683 |
| 23. | Gavioli et al., Proc. Natl. Acad. Sci. USA (1992) 89:5862-5866 |
| 24. | Gonzalez et al., Parasite Immunology (2000) 22:501-514 |
| 25. | Ishioka et al., J. Immunol. (1999) 162:3915-3925 |
| 26. | Jameson and Bevan, Eur. J. Immunol. (1992) 22:2663-2667 |
| 27. | Kast et al., J. Immunol. (1994) 152:3904-3912 |
| 28. | Kast et al., Eur. J. Immunol. (1993) 23:1189-1192 |
| 29. | Kawakami et al., J. Immunol. (1995) 154:3961-3968 |
| 30. | Kawashima et al., Human Immunol. (1998) 59:1-14 |
| 31. | Kozlowski et al., J. Exp. Med. (1992) 175:1417-1422 |
| 32. | Lamonica et al., Hepatology (1999) 30:1088-1098 |
| 33. | Lipford et al., J. Immunol. (1993) 150:1212-1222 |
| 34. | Lustgarten et al., Human Immunology (1997) 52:109-118 |
| 35. | Niedermann et al., Immunol. Rev. (1999) 172:29-48 |
| 36. | Niedermann et al., Proc. Natl. Acad. Sci. USA (1996) 93:8572-8577 |
| 37. | Prezzi et al., Eur. J. Immunol. (2001) 31:894-906 |
| 38. | Rehermann et al., J. Clin. Invest. (1996) 97:1655-1665 |
| 39. | Ressing et al., J. Immunol. (1995) 154:5934-5942 |
| 40. | Rivoltini et al., J. Immunol. (1995) 154:2257-2265 |
| 41. | Ruppert et al., Cell (1993) 74:929-937 |
| 42. | Sarobe et al., Eur. J. Immunol. (1991) 21:1555-1558 |
| 43. | Scognamiglio et al., J. Immunol. (1999) 162:6681-6689 |
| 44. | Sette et al., J. Immunol. (1994) 153:5586-5592 |
| 45. | Sette and Sidney, Curr. Opin. Immunol. (1998) 10:478-482 |
| 46. | Sette et al., in Persistent Viral Infections, Ahmed and Chen (Eds.), John Wiley & Sons (1999) |
| 47. | Sette et al., Immunodominance and Breadth of Cellular Responses (2001) In Press |
| 48. | Shastri et al., J. Immunol. (1995) 155:4339-4346 |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

Docket Number 399632000325

Application Number 09/665,510

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Ralph T. KUBO et al.

Filing Date September 19, 2000

Group Art Unit To Be Assigned

Mailing Date: November __, 2001

- | | |
|-----|---|
| 49. | Sherman et al., J. Exp. Med. (1992) 175:1221-1226 |
| 50. | Snoke et al., J. Immunol. (1993) 151:6815-6821 |
| 51. | Tangri et al., Journal of Experimental Medicine (2001) In Press |
| 52. | Threlkeld et al., J. Immunol. (1997) 159:1648-1657 |
| 53. | Tsai et al., J. Immunol. (1997) 1796-1802 |
| 54. | Van Der Most et al., J. Immunol. (1996) 157:5543-5554 |
| 55. | Van Der Most et al., Virology (1997) 71:5110-5114 |
| 56. | Van Der Most et al., Virology (1998) 240:158-167 |
| 57. | Vitiello et al., J. Immunol. (1996) 157:5555-5562 |
| 58. | Wentworth et al., Eur. J. Immunol. (1996) 26:97-101 |
| 59. | Wilson et al., J. Virol. (2001) 75:4195-4207 |
| 60. | Wizel et al., J. Clin. Invest. (1998) 102:1062-1071 |
| 61. | Yewdell and Bennick, Annu. Rev. Immunol. (1999) 17:51-88 |
| 62. | Yoon et al., Virus Research (1998) 54:23-29 |
| 63. | York and Rock, Annu. Rev. Immunol. (1996) 14:369-396 |
| 64. | Zhang et al., Proc. Natl. Acad. Sci. USA (1993) 90(6):2217-2221 |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.